CAPE TOWN — Consumer goods giant Tiger Brands’ health-care unit Adcock Ingram and several smaller health-care groups face the threat of huge fines for allegedly colluding to fix tenders and divide up the market for intravenous drip solutions.
The Competition Commission said yesterday it had concluded its investigation into alleged collusion between Adcock Ingram Critical Care (AICC), Dismed Criticare and Thusanong Healthcare, and had referred the matter to the Competition Tribunal for prosecution. The commission had asked the t ribunal to apply the maximum penalty allowed by the Competition Act — 10% of turnover — said the commission’s senior legal analyst, Nandi Mokoena.
According to Tiger Brands’ most recent annual report, the company’s turnover was
R16,2bn last year, while Adcock, which is to be unbundled from Tiger, reported turnover of R2,87bn for the same period. If the t ribunal concurs with the commission, the firms could face fines of up to R1,6bn and R287m respectively.
by Tamar Kahn
More.
No comments:
Post a Comment